Nikolaos Almyroudis, MD, FACP

Specialty: Internal Medicine
Department of Medicine

 Request an Appointment
Locations

Roswell Park Main Campus
1-800-ROSWELL (1-800-767-9355)

Dr. Almyroudis is a Buffalo Spree Top Doctor! Top Doctors 2024 See all of our physicians who made this year's list.

Specializing In:

  • Infectious diseases

Research Interests:

  • Infections in hematopoietic stem cell transplant recipients
  • Fungal infections and infections caused by resistant bacteria in patients with malignancies

Positions

Roswell Park Comprehensive Cancer Center

  • Associate Professor of Medicine
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Associate Professor of Medicine

Background

Education and Training

  • MD - Medical School of the National University of Athens, Athens, Greece

Residency

  • Saint Savvas Oncology Hospital, Athens, Greece
  • University of Pittsburgh Medical Center (UPMC) Health System, McKeesport Hospital, McKeesport, PA

Fellowship

  • University of South Florida College of Medicine, Tampa, FL
  • Memorial Sloan-Kettering Cancer Center, New York, NY

Board Certification

  • Internal Medicine, American Board of Internal Medicine
  • Infectious Diseases, American Board of Internal Medicine

Publications

  • Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4. PMID: 22222250.
  • Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012 Mar;18(1):91-6. doi: 10.1177/1078155211402107. Epub 2011 Apr 26. PMID: 21521799.
  • Almyroudis NG, Wetzler M, McCarthy PL Jr, Wang ES, Wongkittiroch K, Hazamy PA, Samonis G, Hahn T, Lesse AJ, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2011 May;32(5):490-6. doi: 10.1086/659408. PMID: 21515980.
  • Grimm MJ, Vethanayagam RR, Almyroudis NG, Lewandowski D, Rall N, Blackwell TS, Segal BH. Role of NADPH oxidase in host defense against aspergillosis. Med Mycol. 2011 Apr;49 Suppl 1(Suppl 1):S144-9. doi: 10.3109/13693786.2010.487077. Epub 2010 Jun 21. PMID: 20560866; PMCID: PMC5494985.
  • Vethanayagam RR, Almyroudis NG, Grimm MJ, Lewandowski DC, Pham CT, Blackwell TS, Petraitiene R, Petraitis V, Walsh TJ, Urban CF, Segal BH. Role of NADPH oxidase versus neutrophil proteases in antimicrobial host defense. PLoS One. 2011;6(12):e28149. doi: 10.1371/journal.pone.0028149. Epub 2011 Dec 7. PMID: 22163282; PMCID: PMC3233573.
  • Almyroudis NG, Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010 Dec;8(12):1451-66. doi: 10.1586/eri.10.141. PMID: 21133669.
  • Partridge-Hinckley K, Liddell GM, Almyroudis NG, Segal BH. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia. 2009 Dec;168(6):329-37. doi: 10.1007/s11046-009-9247-z. PMID: 19859825.
  • Almyroudis NG, Fabian J, Hahn T, Segal BH, Wetzler M, McCarthy PL Jr. Late infectious complications after cord blood stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2009 Nov;28(11):1405-8. doi: 10.1007/s10096-009-0789-2. Epub 2009 Aug 12. PMID: 19672638.
  • Almyroudis NG, Segal BH. Prevention and treatment of invasive fungal diseases in neutropenic patients. Curr Opin Infect Dis. 2009 Aug;22(4):385-93. doi: 10.1097/QCO.0b013e32832e074d. PMID: 19506476.
  • Parameswaran GI, Segal BH, Almyroudis NG. Antifungal agents in hematopoietic stem cell transplantation. Curr Pharm Des. 2008;14(20):2011-21. doi: 10.2174/138161208785061391. PMID: 18691111.
  • Gonzalez AV, Ullmann AJ, Almyroudis NG, Segal BH. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw. 2008 Feb;6(2):175-82. doi: 10.6004/jnccn.2008.0014. PMID: 18319049.
  • Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008 Sep 1;47(5):674-83. doi: 10.1086/590566. PMID: 18637757; PMCID: PMC2671230.
  • Almyroudis NG, Clarke LA, Tucci VT, Greene JN, Vincent AL. Pseudomonas aeruginosa infections of cartilaginous structures. Asian Biomedicine. 2008; 25:361-369
  • Battiwalla M, Hahn T, Padmanabhan S, Nakamura R, Wallace PK, Segal BH, Almyroudis NG, Radovic M, Bajwa RP, Wu Y, McCarthy PL Jr. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant. 2007 Jul;13(7):765-70. doi: 10.1016/j.bbmt.2007.03.009. Epub 2007 May 7. PMID: 17580254.
  • Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007 Jul;51(7):2587-90. doi: 10.1128/AAC.00452-07. Epub 2007 Apr 23. PMID: 17452481; PMCID: PMC1913247.
  • Battiwalla M, McCarthy PL, Becker J, Smith P, Elefante A, Abdelhalim A, McCarthy A, Almyroudis NG, Paplham P, Segal BH. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis. 2007 Mar;9(1):28-32. doi: 10.1111/j.1399-3062.2006.00170.x. PMID: 17313468.
  • Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007 Feb 1;44(3):402-9. doi: 10.1086/510677. Epub 2007 Jan 2. PMID: 17205448.
  • Gupta S, Almyroudis NG, Battiwalla M, Bambach BJ, McCarthy PL, Proefrock AD, Ball D, Paplham P, Varma A, Kwon-Chung J, Segal BH. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2007 Jun;9(2):156-60. doi: 10.1111/j.1399-3062.2006.00189.x. PMID: 17462004.
  • Padmanabhan S, Battiwalla M, Hahn T, Ball D, Paplham P, Brown K, Segal BH, McCarthy P Jr, Almyroudis NG. Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transpl Infect Dis. 2007 Jun;9(2):148-52. doi: 10.1111/j.1399-3062.2006.00188.x. PMID: 17462002.